Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EBITDA (2019 - 2025)

Biodesix (BDSX) has disclosed EBITDA for 7 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 70.42% year-over-year to -$2.0 million, compared with a TTM value of -$27.9 million through Dec 2025, up 19.2%, and an annual FY2025 reading of -$27.9 million, up 19.2% over the prior year.
  • EBITDA was -$2.0 million for Q4 2025 at Biodesix, up from -$7.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$2.0 million in Q4 2025 and bottomed at -$16.4 million in Q1 2023.
  • Average EBITDA over 5 years is -$9.8 million, with a median of -$10.2 million recorded in 2021.
  • The sharpest move saw EBITDA tumbled 340.22% in 2021, then skyrocketed 70.42% in 2025.
  • Year by year, EBITDA stood at -$11.7 million in 2021, then fell by 18.93% to -$13.9 million in 2022, then skyrocketed by 50.54% to -$6.9 million in 2023, then increased by 3.22% to -$6.6 million in 2024, then surged by 70.42% to -$2.0 million in 2025.
  • Business Quant data shows EBITDA for BDSX at -$2.0 million in Q4 2025, -$7.1 million in Q3 2025, and -$9.7 million in Q2 2025.